Observational studies have suggested that vitamin D may reduce inflammation in relapsing-remitting MS, but this has not been clearly confirmed in randomized controlled trials.
To further explore the possible anti-inflammatory effects of vitamin D, investigators from Norway examined the effect of high-dose oral vitamin D (20,000IU/week) on eleven blood markers of inflammation in 68 people with RRMS.
While the oral supplement more than doubled the mean vitamin D level in the blood, it did not have a significant effect on inflammation when compared to the dummy drug.
These results do not confirm an association between increasing vitamin D levels in the blood and reduced inflammation in relapsing-remitting MS, as previously proposed by other studies.
However, the researchers cannot exclude that vitamin D3 supplementation may affect other relevant markers not measured in their trial.
Read the full article (external website opens in a new window)